Literature DB >> 24833031

Stress fracture of the ulna associated with bisphosphonate therapy and use of walking aid.

G S H Chiang, C S H Grace1, K W B Koh, K W B Kelvin, T W Chong, C T Wei, B Y Tan, T B Yeow.   

Abstract

We report a case of a stress fracture of the ulna secondary to long-term bisphosphonate therapy and walking cane. Physicians need to have a high index of suspicion of stress fractures occurring in patients complaining of chronic upper limb pain if they are on bisphosphonate therapy and are using walking aids. Stress fractures of the upper extremities are rare and are usually associated with athletes; however, a few recent case reports have shown an association between stress fractures of the upper extremities and the use of walking aids. The association between increased incidence of upper extremity stress fractures and the use of both bisphosphonates and walking aids in patients has not been well studied, with only one previously reported case. Here, we report a case of a complete stress fracture of the ulna in a 77-year-old female, premorbidly ambulant with walking cane, on long-term bisphosphonates without any pre-existing medical conditions which could result in secondary causes of bone loss. Investigations did not reveal any causes of pathological fracture. This fracture is attributed to the use of long-term bisphosphonate therapy in conjunction with the use of a walking cane. This case highlights the importance of entertaining the possibility of such fractures occurring in any patient who is on bisphosphonate therapy presenting with stress fractures of the upper extremity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24833031     DOI: 10.1007/s00198-014-2739-9

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  15 in total

1.  Low-energy fractures of the humeral shaft and bisphosphonate use.

Authors:  Maria P Yavropoulou; Andrea Giusti; Sharita R Ramautar; Sander Dijkstra; Neveen A T Hamdy; Socrates E Papapoulos
Journal:  J Bone Miner Res       Date:  2012-06       Impact factor: 6.741

2.  Atypical femoral fractures and bisphosphonate use.

Authors:  Christian M Girgis; Doron Sher; Markus J Seibel
Journal:  N Engl J Med       Date:  2010-05-13       Impact factor: 91.245

3.  Evolving data about subtrochanteric fractures and bisphosphonates.

Authors:  Elizabeth Shane
Journal:  N Engl J Med       Date:  2010-03-24       Impact factor: 91.245

4.  Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features.

Authors:  Andrea Giusti; Neveen A T Hamdy; Olaf M Dekkers; Sharita R Ramautar; Sander Dijkstra; Socrates E Papapoulos
Journal:  Bone       Date:  2010-12-31       Impact factor: 4.398

5.  An estimate of the worldwide prevalence and disability associated with osteoporotic fractures.

Authors:  O Johnell; J A Kanis
Journal:  Osteoporos Int       Date:  2006-09-16       Impact factor: 4.507

Review 6.  Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies.

Authors:  Andrea Giusti; Neveen A T Hamdy; Socrates E Papapoulos
Journal:  Bone       Date:  2010-05-20       Impact factor: 4.398

Review 7.  Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-10-01       Impact factor: 6.741

8.  Severely suppressed bone turnover and atypical skeletal fragility.

Authors:  Maja Visekruna; Deborah Wilson; Fergus Eoin McKiernan
Journal:  J Clin Endocrinol Metab       Date:  2008-06-03       Impact factor: 5.958

9.  Stress fractures in athletes: review of 196 cases.

Authors:  Jun Iwamoto; Tsuyoshi Takeda
Journal:  J Orthop Sci       Date:  2003       Impact factor: 1.601

Review 10.  Proximal ulna stress fracture and stress reaction of the proximal radius associated with the use of crutches: a case report and literature review.

Authors:  Nanda Venkatanarasimha; Sridhar Kamath; G Kambouroglou; Simon J Ostlere
Journal:  J Orthop Traumatol       Date:  2009-08-26
View more
  5 in total

1.  Radiological Reversibility of Incomplete Atypical Femoral Fracture with Cessation of Bisphosphonate: Including an Early Stage of Incomplete Fracture.

Authors:  Soo Min Cha; Hyun Dae Shin; Seung Hoo Lee; Jae Woo Shin
Journal:  Indian J Orthop       Date:  2022-04-22       Impact factor: 1.033

Review 2.  Ulnar fractures with bisphosphonate therapy: a systematic review of published case reports.

Authors:  S H S Tan; S Saseendar; B H M Tan; A Pawaskar; V P Kumar
Journal:  Osteoporos Int       Date:  2014-09-17       Impact factor: 4.507

3.  Effect of Long-Term Use of Bisphosphonates on Forearm Bone: Atypical Ulna Fractures in Elderly Woman with Osteoporosis.

Authors:  Yusuf Erdem; Zafer Atbasi; Tuluhan Yunus Emre; Gülis Kavadar; Bahtiyar Demiralp
Journal:  Case Rep Orthop       Date:  2016-08-10

4.  Treatment of Atypical Fracture of the Ulnar Diaphysis by Open Reduction and Internal Fixation with Teriparatide.

Authors:  Hiroki Ito; Naohisa Miyakoshi; Yuji Kasukawa; Takeshi Sato; Hitoshi Kubota; Hiroshi Sasaki; Takashi Mizutani; Yoichi Shimada
Journal:  Case Rep Orthop       Date:  2019-09-04

Review 5.  Treatment strategy for atypical ulnar fracture due to severely suppressed bone turnover caused by long-term bisphosphonate therapy: a case report and literature review.

Authors:  Kensaku Abe; Hiroaki Kimura; Norio Yamamoto; Shingo Shimozaki; Takashi Higuchi; Yuta Taniguchi; Takaaki Uto; Hiroyuki Tsuchiya
Journal:  BMC Musculoskelet Disord       Date:  2020-12-03       Impact factor: 2.362

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.